Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 626

1.

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H.

PLoS Med. 2005 Mar;2(3):e73. Epub 2005 Feb 22.

2.

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T.

Clin Cancer Res. 2006 Oct 1;12(19):5764-9.

3.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2006 Nov 1;12(21):6494-501.

4.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. Epub 2007 Dec 18.

5.

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.

Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2008 Nov 15;14(22):7519-25. doi: 10.1158/1078-0432.CCR-08-0151.

6.

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S.

Clin Cancer Res. 2008 Nov 1;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455.

7.

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T.

J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52.

8.

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE.

PLoS Med. 2005 Jan;2(1):e17. Epub 2005 Jan 25.

9.

XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

Pietanza MC, Lynch TJ Jr, Lara PN Jr, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA.

J Thorac Oncol. 2012 Jan;7(1):219-26. doi: 10.1097/JTO.0b013e31822eebf9.

10.

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K.

Lung Cancer. 2010 May;68(2):198-203. doi: 10.1016/j.lungcan.2009.05.022. Epub 2009 Jul 8.

PMID:
19589612
11.

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.

Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T.

Clin Cancer Res. 2010 Nov 15;16(22):5489-98. doi: 10.1158/1078-0432.CCR-10-1371. Epub 2010 Nov 9.

12.
13.

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H.

Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. Epub 2004 Aug 25.

14.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. Epub 2005 May 16.

15.

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.

Clin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15.

16.

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.

Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel RJ, Jänne PA.

Clin Cancer Res. 2009 Apr 15;15(8):2630-6. doi: 10.1158/1078-0432.CCR-08-2592. Epub 2009 Apr 7.

17.

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K.

Clin Cancer Res. 2006 Jul 1;12(13):3915-21.

18.

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).

Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.

Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.

PMID:
22082647
19.

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Jänne PA.

Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. doi: 10.1016/S0169-5002(08)70099-0. Review.

PMID:
18513582
20.

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.

Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.

Supplemental Content

Support Center